Filing Details

Accession Number:
0001104659-25-055974
Form Type:
4
Zero Holdings:
No
Publication Time:
2025-06-03 16:15:15
Reporting Period:
2025-05-30
Filing Date:
2025-06-03
Accepted Time:
2025-06-03 16:15:15
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1649904 Rhythm Pharmaceuticals Inc. RYTM () 4
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1636385 C Hunter Smith C/O Rhythm Pharmaceuticals, Inc.
222 Berkeley Street, 12Th Floor
Boston MA 02116
Chief Financial Officer No Yes No No
Transaction Summary
Sold: 23,400 shares Avg. Price: $61.41 Total Value: $1,437,010.37
Number of Shares After Transactions: 109,929 shares
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2025-05-30 23,400 $6.88 133,329 No 4 M Direct
Common Stock Disposition 2025-05-30 4,407 $60.93 128,922 No 4 S Direct
Common Stock Disposition 2025-05-30 18,993 $61.52 109,929 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 S Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Stock Options (Right to Buy) Disposition 2025-05-30 23,400 $0.00 23,400 $6.88
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
77,194 2027-08-08 No 4 M Direct
Footnotes
  1. The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on February 28, 2025.
  2. The price reported in Column 4 is a weighted average price. The securities were sold in multiple transactions at prices ranging from $60.33 to $61.32 per common stock. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
  3. The price reported in Column 4 is a weighted average price. The securities were sold in multiple transactions at prices ranging from $61.33 to $61.62 per common stock. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
  4. The stock option is fully vested.